Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 4, 2012, Pages 393-398

  Kennedy, Andrew ^a,b,c,d   Coldwell, Douglas ^e   Sangro, Bruno ^g   Wasan, Harpreet ^h   Salem, Riad ^f  

^a Wake Radiology Oncology   (United States)

^b North Carolina State University   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF LOUISVILLE HOSPITAL   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g UNIVERSITY OF NAVARRA   (Spain)

^h HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

carcinoid; hepatic; metastases; SIRT; Yttrium 90

Indexed keywords

ANTINEOPLASTIC AGENT; IODINE 131; YTTRIUM 90;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; HUMAN; LIVER CANCER; LIVER METASTATIC NEUROENDOCRINE TUMOR; MORBIDITY; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS ISLET CELL CARCINOMA; QUALITY OF LIFE; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE;

BRACHYTHERAPY; CLINICAL TRIALS AS TOPIC; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEUROENDOCRINE TUMORS; PROGNOSIS;

EID: 84864368497     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182005768     Document Type: Review

References (39)

1. Madoff D, Gupta S, Ahrar K, et al. Update on the management of neuroendocrine hepatic metastases. J Vasc Interv Radiol. 2006; 17:1235-1250. (Pubitemid 44259008)
2. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130: 677-682.
3. Chamberlain RS, Brown KT, Canes D, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-445. (Pubitemid 30181109)
4. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery. 1992;111:48-54.
5. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg. 2002;26:985-990. (Pubitemid 36920297)
6. Kolby L, Persson G, Franzen S, et al. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg. 2003;90: 687-693. (Pubitemid 36760596)
7. O'Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:585-594. (Pubitemid 41447720)
8. Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq 90YDOTATOC. J Nucl Med. 2002;43:610-616. (Pubitemid 34507110)
9. McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: Hepatic intraarterial 90YDOTA- lanreotide as effective palliative therapy. Radiology. 2005;237:718-726. (Pubitemid 41507917)
10. Valkema R, Pauwels S, Kvols LK, et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,- Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36:147-156. (Pubitemid 43320450)
11. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3] octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26: 2124-2130.
12. Delpassand ES, Sims-Mourtada J, Saso H, et al. Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm. 2008;23:292-300. (Pubitemid 351931457)
13. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol. 2005;23:4897-4904. (Pubitemid 46223995)
14. McCollum AD, Kulke MH, Ryan DP, et al. Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol. 2004;27:485-488. (Pubitemid 39371944)
15. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer. 1999;86: 944-948. (Pubitemid 29439847)
16. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351-1355.
17. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004;101:1987-1993. (Pubitemid 39425373)
18. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer. 2005;104: 1590-1602. (Pubitemid 41437421)
19. Ruutiainen AT, Soulen MC, Tuite CM, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18:847-855. (Pubitemid 46963614)
20. Kalinowski M, Dressler M, König A, et al. Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: A prospective single center study. Digestion. 2009;79:137-142.
21. Kennedy AS, Dezarn W, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Ymicrospheres: Early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
22. King J, Quinn R, Glenn D, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113:921-929.
23. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg. 2008;247: 1029-1035. (Pubitemid 351770424)
24. Meranze SG, Bream PR, Grzeszczak E, et al. Phase II clinical trial of yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. Presented as a poster at the Society of Interventional Radiology (SIR) 32nd Annual Scientific Meeting 2007; Abs 422.
25. McGrath S, Kennedy A, Dezarn W. Resin 90Y-microsphere radioembolisation is effective in controlling hepatic metastases from neuroendocrine primary cancers. Presented at the Emerging Trends in Radioembolization using Microspheres: Third Annual Clinical Symposium; 4-5 May 2007; Abs.
26. Kennedy A, Dezarn W, McNeillie P, et al. Fractionation, dose selection, and response of hepatic metastases of neuroendocrine tumors after 90Y-microsphere brachytherapy. Presented as a poster at 2006 Annual American Brachytherapy Society Meeting, Brachytherapy. 2006;5:103: Abs P-75.
27. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19:145-151.
28. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376. (Pubitemid 23073154)
29. Kavadas V, Blazeba JM, Conroy T, et al. Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer. Eur J Cancer. 2003;39:1259-1263. (Pubitemid 36579197)
30. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Radiat Oncol Biol Phys. 2007;68:13-23. (Pubitemid 46589861)
31. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: A comprehensive literature review. J Vasc Interv Radiol. 2009;20: 1121-1130; quiz 31.
32. Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494-1500.
33. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458-511. (Pubitemid 38780668)
34. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717-1751. (Pubitemid 40692562)
35. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-581.
36. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: Contrasting Norway and North America. Cancer. 2008;113:2655-2664.
37. Yao JC, Hassan M, Phan A, et al. One hundred years after ''carcinoid'': Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
38. Frilling A, Li J, Malamutmann E, Schmid KW, et al. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg. 2009;96:175-184.
39. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-783.